13 December 2022
ECO Animal Health Group plc
("ECO" or the "Company")
Deferred Share Option Awards to Executive Director & PDMRs
ECO Animal Health Group plc announces that on 12 December 2022, deferred nominal cost share options were granted under the Company's Deferred Bonus Plan ("DBS") over 45,606 ordinary shares in the Company (representing approximately 0.07 percent of the Company's issued share capital) to an Executive Director and members of the Company's Executive Leadership Team ("ELT") listed below. These awards relate to the deferral of 33% and 20% of the annual bonus for Executive Directors and members of ELT respectively earned in respect of the Company's financial year ended 31 March 2022.
| Name | Position | Number of Deferred Share Options |
| Chris Wilks | Chief Financial Officer | 4,309 |
| Hafid Benchaoui | Head of Global Research and Development | 3,666 |
| Andrew Buglass | Business Unit Head - China & Japan | 6,872 |
| Seamus Long | Global Director of Operations | 2,260 |
| Jordi Mora | Global Technical Services Director | 4,507 |
| Piotr Postepski | Global Director of Sales | 14,926 |
| Oscar Romero-Galindo | Head of Global Marketing | 9,066 |
As indicated in the Circular to shareholders dated 4 February 2021, the DBS has been established to allow the Remuneration Committee to require a significant part of the annual bonuses paid to Executive Directors and senior management to be deferred in exchange for an award of nominal cost options which vest after 3 years.
For further information please contact:
About ECO Animal Health ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products.
| | ||||||||||
| | |
PDMR Notification - ECO DBS Deferred Share Option Awards
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||||||
| a. | Name | 1. Chris Wilks 2. Hafid Benchaoui 3. Andrew Buglass 4. Seamus Long 5. Jordi Mora 6. Piotr Postepski 7. Oscar Romero-Galindo | ||||||||||||||||
| 2. | Reason for the notification | |||||||||||||||||
| a. | Position/status | 1. Chief Financial Officer 2. Head of Global Research and Development 3. Business Unit Head - China & Japan 4. Global Director of Operations 5. Global Technical Services Director 6. Global Director of Sales 7. Head of Global Marketing | ||||||||||||||||
| b. | Initial notification /Amendment | Initial notification | ||||||||||||||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||
| a. | Name | Eco Animal Health Group Plc | ||||||||||||||||
| b. | LEI | 2138009XN9DJ3YP70B55 | ||||||||||||||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||||||
| a. | Description of the Financial instrument, type of instrument Identification code | Options over ordinary shares of 5p each.
GB0032036807
| ||||||||||||||||
| b. | Nature of the transaction | Award of nominal cost share options under the Company's DBS. | ||||||||||||||||
| c. | Price(s) and volume(s) | Numbers 1 to 7 in the left-hand column correspond to the relevant PDMR as detailed in boxes 1a and 2a above.
| ||||||||||||||||
| d. | Aggregated information Aggregated volume Price
|
n/a
| ||||||||||||||||
| e. | Date of the transaction | 12 December 2022 | ||||||||||||||||
| f. | Place of the transaction | Outside a trading venue.
| ||||||||||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
